Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – Still a Buy?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) gapped up before the market opened on Friday . The stock had previously closed at $24.91, but opened at $26.45. Kestra Medical Technologies shares last traded at $27.15, with a volume of 105,572 shares changing hands.

Analyst Ratings Changes

A number of research firms have recently commented on KMTS. Piper Sandler raised their price objective on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday. BTIG Research assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, October 8th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th. Finally, Wells Fargo & Company boosted their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Kestra Medical Technologies Stock Up 5.1%

The company has a market cap of $1.35 billion and a P/E ratio of -10.26. The stock has a 50-day moving average of $25.54 and a two-hundred day moving average of $20.80. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.84 and a current ratio of 6.84.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Thursday, September 11th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.16. The business had revenue of $19.37 million for the quarter, compared to analysts’ expectations of $17.68 million.

Institutional Trading of Kestra Medical Technologies

Several hedge funds have recently added to or reduced their stakes in KMTS. Yu Fan purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $56,880,000. T. Rowe Price Investment Management Inc. purchased a new position in Kestra Medical Technologies in the 1st quarter worth approximately $56,613,000. Omega Fund Management LLC bought a new stake in Kestra Medical Technologies in the first quarter valued at approximately $44,754,000. Alliancebernstein L.P. boosted its stake in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the period. Finally, Eventide Asset Management LLC grew its holdings in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock worth $17,584,000 after purchasing an additional 785,557 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.